Midbrain organoids for in vitro
disease modeling

OrganoTherapeutics is a spin-off project from the University of Luxembourg. OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease. We screen for novel compounds which can be therapeutic for different patient sub-groups.

Classic approach

Target Identified
Active molecule selected
PHENOTYPING
Testing
Pre-clinical testing
Clinical trials

OT approach

Phenotyping Screening
Active molecule selected
Pre-clinical testing
Clinical trials

Our expertise

HUMAN-SPECIFIC MODELS
Proprietary 3D models derived from healthy individual and PD patient material

DRUG EFFECTIVENESS
In the minibrains => identification of cellular defects which are missed in conventional methods. The therapeutic potential of compounds can be identified

AUTOMATED ANALYSIS
The screening platform allows fully automated image and data analyses using artificial intelligence approaches

LIBRARY SCREENING
OT has access to unique libraries of chemically defined molecules (LDC) and natural molecules extracted from marine and floral organisms from Australia (Griffith University)

Find out more

Our team

Javier Jarazo, PHD

Founder

Expert in stem cell models, phenotyping screening and computational data analysis.

JENS SCHWAMBORN, PHD

Founder

Professor at the University of Luxembourg. Neuroscientist expert in stem cell research and Parkinson’s disease research.

ISABEL ROSETY, PHD

LEAD PROJECT SCIENTIST

Expert in 3D cell culture systems and Parkinson’s Disease research.

GEMMA GÓMEZ-GIRÓ

LEAD PROJECT SCIENTIST

Expert in organoid and assembloid systems, neurodegeneration and Parkinson’s Disease research.

SÒNIA SABATÉ-SOLER, PHD

PROJECT MANAGER | BUSINESS DEVELOPER

Expert in stem cell models, organoid and assembloid optimization and neuroinflammation.